GlassScriptPhysician profile
Tony J Fiore
NPI 1447283973
$3,136.81
in general payments reported to CMS, 2019-2025
35 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $467 · 2021: $182 · 2022: $205 · 2023: $407 · 2024: $499 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $606.26 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $369.72 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $349.32 | 2021-2025 | |
| Amgen INC. | $260.40 | 2019-2020 | |
| Pfizer INC. | $238.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $152.03 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Allergan, INC. | $146.63 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $117.06 | 2019-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $103.05 | 2019-2024 | |
| Lundbeck LLC | $82.44 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $68.82 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $57.56 | 2019 | |
| Abbott Laboratories | $55.52 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.58 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.35 | 2022-2023 | Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.36 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.29 | 2023-2024 | |
| Glaxosmithkline, LLC. | $28.77 | 2019 | |
| Vanda Pharmaceuticals INC. | $26.33 | 2020 | |
| Exact Sciences Corporation | $24.22 | 2024 | Cologuard Collection Kit |
| Tonix Medicines, INC. | $23.70 | 2025 | Tonmya |
| Phathom Pharmaceuticals, INC. | $23.31 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $18.24 | 2021 | |
| Boston Scientific Corporation | $17.60 | 2019 | |
| Eisai INC. | $16.19 | 2020 | |
| Inspire Medical Systems, INC. | $16.13 | 2023 | Inspire |
| Sanofi-Aventis U.S. LLC | $13.95 | 2020 | |
| Neurelis, INC. | $13.81 | 2020 | |
| Shire North American Group INC | $13.53 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.79 | 2019 | |
| Clarus Therapeutics INC. | $10.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Fiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.